• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

花生挑战后出现延迟症状和直立不耐受。

Delayed symptoms and orthostatic intolerance following peanut challenge.

机构信息

National Heart & Lung Institute, Imperial College London, London, UK.

Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.

出版信息

Clin Exp Allergy. 2021 May;51(5):696-702. doi: 10.1111/cea.13865. Epub 2021 Mar 21.

DOI:10.1111/cea.13865
PMID:33715235
Abstract

BACKGROUND

Clinical reactions to Oral Food Challenge (OFC) in peanut-allergic individuals have been well-characterised, but rates and phenotypes of symptom recurrence beyond the first hour after objective symptoms are less well-characterised.

OBJECTIVE

To evaluate the rate of new-onset symptoms occurring at least 1 h after stopping OFC in peanut-allergic children and adults undergoing peanut-OFC.

METHODS

We prospectively collected data relating to adverse events following positive reactions at double-blind, placebo-controlled food challenges (DBPCFC) to peanut in children and adults evaluated for eligibility to participate in two clinical trials (NCT02149719, NCT02665793). The trials included people aged 8 to 45 with primary, IgE-mediated peanut allergy at DBPCFC. The challenge protocol included consumption of a light meal 1 h after reaction.

RESULTS

A total of 121 participants (64 children, 57 adults) had immediate, objective symptoms at DBPCFC, 25 (17 children, 8 adults) with anaphylaxis. Thirty-three (27%) had progression or recurrence of symptoms ≥ 1 h after objective clinical reaction, of whom 8 developed anaphylaxis. In 23 cases, the onset of new symptoms was associated with consumption of a light meal. In eight cases, symptoms were limited to a symptomatic postural fall in blood pressure noted in preparation for discharge, without any other new features of an allergic reaction.

CONCLUSIONS & CLINICAL RELEVANCE: Progressive or new-onset symptoms ≥1 h following initial allergic reaction at OFC are common and can include orthostatic hypotension. Recurrent symptoms may be temporally associated with food consumption.

摘要

背景

口服食物激发试验(OFC)中花生过敏个体的临床反应已有很好的描述,但在客观症状出现后 1 小时后症状复发的发生率和表型特征描述较少。

目的

评估在进行花生-OFC 的花生过敏儿童和成人中,OFC 后至少 1 小时出现新症状的发生率。

方法

我们前瞻性地收集了在双盲、安慰剂对照食物激发试验(DBPCFC)中对花生产生阳性反应后出现不良事件的数据,这些数据与儿童和成人参加两项临床试验的资格评估有关(NCT02149719、NCT02665793)。这些试验包括在 DBPCFC 时患有原发性、IgE 介导的花生过敏的 8 至 45 岁人群。激发方案包括在反应后 1 小时内食用清淡餐。

结果

共有 121 名参与者(64 名儿童,57 名成人)在 DBPCFC 时出现即刻、客观的症状,其中 25 名(17 名儿童,8 名成人)出现过敏反应。33 名(27%)在客观临床反应后≥1 小时出现症状进展或复发,其中 8 名发展为过敏反应。在 23 例中,新症状的发作与清淡餐的摄入有关。在 8 例中,症状仅限于在准备出院时出现的症状性体位性低血压,没有过敏反应的其他新特征。

结论和临床相关性

在 OFC 初始过敏反应后 1 小时后出现进行性或新症状是常见的,可能包括直立性低血压。复发的症状可能与食物摄入有关。

相似文献

1
Delayed symptoms and orthostatic intolerance following peanut challenge.花生挑战后出现延迟症状和直立不耐受。
Clin Exp Allergy. 2021 May;51(5):696-702. doi: 10.1111/cea.13865. Epub 2021 Mar 21.
2
Predicting reactivity threshold in children with anaphylaxis to peanut.预测儿童花生过敏反应性阈值。
Clin Exp Allergy. 2018 Apr;48(4):415-423. doi: 10.1111/cea.13078. Epub 2018 Jan 25.
3
Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis.利用食物激发试验数据为食物过敏消费者的管理提供信息:一项基于个体参与者数据的系统评价和荟萃分析。
J Allergy Clin Immunol. 2021 Jun;147(6):2249-2262.e7. doi: 10.1016/j.jaci.2021.01.025. Epub 2021 Feb 9.
4
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.AR101 口服免疫治疗欧洲花生过敏儿童的疗效和安全性(ARTEMIS):一项多中心、双盲、随机、安慰剂对照 3 期试验。
Lancet Child Adolesc Health. 2020 Oct;4(10):728-739. doi: 10.1016/S2352-4642(20)30234-0. Epub 2020 Jul 20.
5
Cardiovascular changes during peanut-induced allergic reactions in human subjects.人体花生过敏反应过程中心血管变化。
J Allergy Clin Immunol. 2021 Feb;147(2):633-642. doi: 10.1016/j.jaci.2020.06.033. Epub 2020 Jul 21.
6
Thresholds of clinical reactivity to milk, egg, peanut and sesame in immunoglobulin E-dependent allergies: evaluation by double-blind or single-blind placebo-controlled oral challenges.免疫球蛋白E介导的牛奶、鸡蛋、花生和芝麻过敏的临床反应阈值:通过双盲或单盲安慰剂对照口服激发试验进行评估。
Clin Exp Allergy. 2003 Aug;33(8):1046-51. doi: 10.1046/j.1365-2222.2003.01734.x.
7
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.AR101 在花生过敏口服免疫治疗中的疗效和安全性:ARC001 的结果,一项随机、双盲、安慰剂对照的 2 期临床试验。
J Allergy Clin Immunol Pract. 2018 Mar-Apr;6(2):476-485.e3. doi: 10.1016/j.jaip.2017.09.016. Epub 2017 Oct 31.
8
AR101 Oral Immunotherapy for Peanut Allergy.AR101 口服免疫疗法治疗花生过敏。
N Engl J Med. 2018 Nov 22;379(21):1991-2001. doi: 10.1056/NEJMoa1812856. Epub 2018 Nov 18.
9
Parental anxiety before and after food challenges in children with suspected peanut and hazelnut allergy.疑似花生和榛子过敏儿童食物挑战前后的父母焦虑。
Pediatr Allergy Immunol. 2010 Mar;21(2 Pt 2):e439-45. doi: 10.1111/j.1399-3038.2009.00929.x. Epub 2009 Aug 17.
10
Three peanut-allergic/sensitized phenotypes with gender difference.三种具有性别差异的花生过敏/致敏表型。
Clin Exp Allergy. 2016 Dec;46(12):1596-1604. doi: 10.1111/cea.12791. Epub 2016 Sep 26.

引用本文的文献

1
Who Needs Epinephrine? Anaphylaxis, Autoinjectors, and Parachutes.谁需要肾上腺素?过敏反应、自动注射器和降落伞。
J Allergy Clin Immunol Pract. 2023 Apr;11(4):1036-1046. doi: 10.1016/j.jaip.2023.02.002. Epub 2023 Feb 14.
2
Predicting probability of tolerating discrete amounts of peanut protein in allergic children using epitope-specific IgE antibody profiling.使用表位特异性 IgE 抗体分析预测过敏儿童耐受离散量花生蛋白的概率。
Allergy. 2022 Oct;77(10):3061-3069. doi: 10.1111/all.15477. Epub 2022 Aug 17.
3
Emergency treatment of anaphylaxis: concise clinical guidance.
过敏反应的紧急处理:简明临床指南。
Clin Med (Lond). 2022 Jul;22(4):332-339. doi: 10.7861/clinmed.2022-0073.
4
Improving Severity Scoring of Food-Induced Allergic Reactions: A Global "Best-Worst Scaling" Exercise.改善食物过敏反应严重程度评分:全球“最佳最差标度”实践。
J Allergy Clin Immunol Pract. 2021 Nov;9(11):4075-4086.e5. doi: 10.1016/j.jaip.2021.06.056. Epub 2021 Jul 19.
5
Evidence update for the treatment of anaphylaxis.过敏反应治疗的证据更新
Resuscitation. 2021 Apr 23;163:86-96. doi: 10.1016/j.resuscitation.2021.04.010.